Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

synthetic MVA-based SARS-CoV-2 vaccine COH04S1

A vaccine comprised of a synthetic modified Vaccinia virus Ankara (sMVA) viral vector encoding the two severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) surface antigens spike (S) and nucleocapsid (N) proteins, with potential immunizing activity against SARS-CoV-2. Upon administration of the sMVA-based SARS-CoV-2 vaccine COH04S1, the SARS-CoV-2 S and N proteins are expressed in cells and presented to the immune system. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection.
Synonym:SARS-CoV-2 vaccine COH04S1
sMVA-based SARS-CoV-2 vaccine COH04S1
Code name:COH04S1
Search NCI's Drug Dictionary